Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in clinical trials Tirzepatide 15 mg (Zepbound): ~21% body weight loss at 72 weeks in clinical trials Real-world data shows lower results: Cleveland Clinic research from 2025 found average weight loss of 7.7% with semaglutide and 12.4% with tirzepatide at one year in routine clinical practice
This further demonstrates its ability to enhance focus and mental clarity across various scenarios
Servings: 30
In conclusion, while more long-term data and randomized controlled trials are necessary to establish the definitive renoprotective effects of Tirzepatide, current evidence is promising
Huang, T., Zhang, K., Sun, L., Xue, X., Zhang, C., Shu, Z., & Wang, J